Results 41 to 50 of about 592,463 (304)

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Annals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
wiley   +1 more source

Effects of behavioural activation on substance use and depression: a systematic review

Substance Abuse Treatment, Prevention, and Policy, 2018
Introduction Substance use and depression co-occurrence is a frequent phenomenon and an important public health concern. Given the clinical implications and the high prevalence of both disorders, effective interventions are needed.
Carmela Martínez-Vispo, Úrsula Martínez, Ana López-Durán, Elena Fernández del Río, Elisardo Becoña   +4 more
doaj   +1 more source

[18F]Fluorodeprenyl‐D2 PET as a Tool to Monitor Disease Activity in GAD65‐Ab Autoimmune Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate [18F]fluorodeprenyl‐D2 ([18F]F‐DED) positron‐emission tomography (PET) imaging as a biomarker of disease activity in autoimmune encephalitis (AIE) associated with glutamic acid decarboxylase 65 (GAD65) antibodies. Methods [18F]F‐DED PET was performed in 25 GAD65‐AIE patients and 8 controls using dynamic (0–60 min) and ...
Julia S. Dorneich, Jonathan A. Gernert, Hanna Zimmermann, Lisa Tagnin, Marianthi Zeinaki, Laura Sanzo, Letizia Vogler, Elisabeth Kaufmann, Justina Dargvainiene, Frank Leypoldt, Gérard N. Bischof, Robert Perneczky, Boris‐Stephan Rauchmann, Simon Lindner, Günter U. Höglinger, Rudolf A. Werner, Martin Kerschensteiner, Tania Kümpfel, Matthias Brendel, Franziska S. Thaler   +19 more
wiley   +1 more source

How a sample of English stop smoking services and vape shops adapted during the early COVID-19 pandemic: a mixed-methods cross-sectional survey

Harm Reduction Journal, 2021
Background The COVID-19 pandemic in England led to major changes in the delivery of support via stop smoking services (SSS) and to the widespread temporary closure of bricks and mortar e-cigarette retailers (vape shops herein).
Sharon Cox, Emma Ward, Louise Ross, Caitlin Notley   +3 more
doaj   +1 more source

Cytisine for smoking cessation [PDF]

Canadian Medical Association Journal, 2018
Cytisine, primarily derived from the Cytisus laburnum plant (which inspired the development of varenicline), is a partial agonist of the α4β2 nicotinic acetylcholine receptor responsible for central effects of nicotine.[1][1] Oral cytisine reaches peak concentration two hours postdose[2][2] and ...
Taleen, Karnieg, Xiang, Wang
openaire   +2 more sources

White Matter Hyperintensity Burden and Short‐Interval Change Associated With Sleep Apnoea in the UK Biobank

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background and Purpose White matter hyperintensities (WMH) are a core neuroimaging marker of cerebral small vessel disease (CSVD). Sleep apnoea (SA) is a recognized vascular risk factor, but its associations with regional WMH burden, short‐interval WMH change and cognitive performance in population‐based cohorts remain incompletely defined. We
Peng Cheng, Diego Z. Carvalho, Shahid Karim, Anwar Chahal, Virend K. Somers   +4 more
wiley   +1 more source

Development and evaluation of STAR - an expert digital platform supporting training and delivery of cessation interventions by healthcare professionals.

Tobacco Prevention and Cessation, 2017
Introduction Access to smoking cessation treatment is limited in many countries. Digital tools could support healthcare professionals (HCPs) who have limited training and resources to deliver evidence-based cessation treatment to patients.
Aleksandra Herbeć, Andy McEwen, Witold Zatoński   +2 more
doaj   +1 more source

Hypnotherapy for smoking cessation [PDF]

, 1998
Hypnotherapy is widely promoted as a method for aiding smoking cessation. It is proposed to act on underlying impulses to weaken the desire to smoke or strengthen the will to stop.The objective of this review was to evaluate the effects of hypnotherapy for smoking cessation.We searched the Cochrane Tobacco Addiction Group trials register.We considered ...
N C, Abbot, L F, Stead, A R, White, J, Barnes, E, Ernst   +4 more
openaire   +2 more sources

Incentives for smoking cessation [PDF]

Cochrane Database of Systematic Reviews, 2015
Material or financial incentives are widely used in an attempt to precipitate or reinforce behaviour change, including smoking cessation. They operate in workplaces, in clinics and hospitals, and to a lesser extent within community programmes. In this third update of our review we now include trials conducted in pregnant women, to reflect the ...
Kate, Cahill, Jamie, Hartmann-Boyce, Rafael, Perera   +2 more
openaire   +2 more sources

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand, Seyed Hossein Aghamiri, Saeed Mohmammad Soleymani, Shadiyeh Bararpoor Poshkohi, Samaneh Masoudi, Hadi Esmaily   +5 more
wiley   +1 more source